Relationship between HuR and tumor drug resistance.
Cancer
Drug resistance
HuR
RNA-binding protein
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
21
08
2022
accepted:
31
01
2023
medline:
12
6
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
Human resistance protein R (HuR), also known as embryonic lethal abnormal visual-like protein (ELAVL1), is an RNA-binding protein widely expressed in vivo that affects the mRNA stability of targeted and is involved in post-transcriptional regulation. Recent studies have shown that HuR is aberrantly expressed in different human cancers and is an essential factor in poor clinical prognosis. The role of HuR in numerous tumors suggests that it could be a new target for tumor therapy and as a marker for efficacy and prognostic assessment. This review focuses on the relationship between HuR and drug resistance in different tumors and briefly describes the structure, function, and inhibitors of HuR. We summarize the mechanisms by which HuR causes tumor resistance and the molecular targets affected.
Identifiants
pubmed: 36947360
doi: 10.1007/s12094-023-03109-5
pii: 10.1007/s12094-023-03109-5
doi:
Substances chimiques
ELAV-Like Protein 1
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1999-2014Subventions
Organisme : National Natural Science Foundation of China-Zhejiang Joint Fund for the Integration of Industrialization and Informatization
ID : 81672474
Organisme : National Natural Science Foundation of China-Zhejiang Joint Fund for the Integration of Industrialization and Informatization
ID : 81874049
Informations de copyright
© 2023. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Kozar I, Margue C, Rothengatter S, Haan C, Kreis S. Many ways to resistance: how melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer. 2019;1871:313–22.
pubmed: 30776401
doi: 10.1016/j.bbcan.2019.02.002
Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18:43–73.
pubmed: 23237552
pmcid: 3597235
doi: 10.1615/CritRevOncog.v18.i1-2.40
Gebauer F, Schwarzl T, Valcárcel J, Hentze MW. RNA-binding proteins in human genetic disease. Nat Rev Genet. 2021;22:185–98.
pubmed: 33235359
doi: 10.1038/s41576-020-00302-y
Choi PS, Thomas-Tikhonenko A. RNA-binding proteins of COSMIC importance in cancer. J Clin Invest [Internet]. Am Soc Clin Investigation; 2021 [cited 2022 Feb 19]; 131. Available from: https://www.jci.org/articles/view/151627
Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet. 2014;15:829–45.
pubmed: 25365966
doi: 10.1038/nrg3813
Kang D, Lee Y, Lee J-S. RNA-binding proteins in cancer: functional and therapeutic perspectives. Cancers (Basel). 2020;12:E2699.
doi: 10.3390/cancers12092699
Beauchamp P, Nassif C, Hillock S, van der Giessen K, von Roretz C, Jasmin BJ, et al. The cleavage of HuR interferes with its transportin-2-mediated nuclear import and promotes muscle fiber formation. Cell Death Differ. 2010;17:1588–99.
pubmed: 20379198
doi: 10.1038/cdd.2010.34
Wu M, Tong CWS, Yan W, To KKW, Cho WCS. The RNA binding protein HuR: a promising drug target for anticancer therapy. Curr Cancer Drug Targets. 2019;19:382–99.
pubmed: 30381077
doi: 10.2174/1568009618666181031145953
Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer–a quantitative western blot analysis. Ann Neurol. 1990;27:544–52.
pubmed: 2163235
doi: 10.1002/ana.410270515
Izquierdo JM. Hu Antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition*. J Biological Chem [Internet]. Elsevier; 2008 [cited 2022 Feb 26]; 283:19077–84. Available from: https://www.jbc.org/article/S0021-9258(20)81507-5/abstract
Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, et al. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol [Internet]. 2000 [cited 2022 Feb 26]; 20:760–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC85192/
Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci. 2008;65:3168–81.
pubmed: 18581050
pmcid: 2580827
doi: 10.1007/s00018-008-8252-6
Pabis M, Popowicz GM, Stehle R, Fernández-Ramos D, Asami S, Warner L, et al. HuR biological function involves RRM3-mediated dimerization and RNA binding by all three RRMs. Nucleic Acids Res [Internet]. 2019 [cited 2022 Feb 26]; 47:1011–29. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344896/
García-Mauriño SM, Rivero-Rodríguez F, Velázquez-Cruz A, Hernández-Vellisca M, Díaz-Quintana A, De la Rosa MA, et al. RNA binding protein regulation and cross-talk in the control of AU-rich mRNA fate. Front Mol Biosci. 2017;4:71.
pubmed: 29109951
pmcid: 5660096
doi: 10.3389/fmolb.2017.00071
Dolicka D, Sobolewski C, de Correia SM, Gjorgjieva M, Foti M. mRNA post-transcriptional regulation by AU-rich element-binding proteins in liver inflammation and cancer. Int J Mol Sci. 2020;21:E6648.
doi: 10.3390/ijms21186648
Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, et al. Cytoplasmic HuR status predicts disease-free survival in resected pancreatic cancer: a post-hoc analysis from the international phase III ESPAC-3 clinical trial. Ann Surg. 2018;267:364–9.
pubmed: 27893535
doi: 10.1097/SLA.0000000000002088
Eberhardt W, Nasrullah U, Haeussler K. Inhibition of caspase-2 translation by the mRNA binding protein HuR: a novel path of therapy resistance in colon carcinoma cells?. Cells [Internet]. 2019 [cited 2022 Feb 28]; 8:797. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721497/
Latorre E, Tebaldi T, Viero G, Spartà AM, Quattrone A, Provenzani A. Mol Cancer. 2012;11:13.
pubmed: 22436134
pmcid: 3325864
doi: 10.1186/1476-4598-11-13
Guo J, Lv J, Chang S, Chen Z, Lu W, Xu C, et al. Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget. 2016;7:45249–62.
pubmed: 27303922
pmcid: 5216720
doi: 10.18632/oncotarget.9932
Bhatnagar N, Li X, Padi SKR, Zhang Q, Tang M-S, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010;1: e105.
pubmed: 21368878
pmcid: 3004480
doi: 10.1038/cddis.2010.85
Janakiraman H, House RP, Talwar S, Courtney SM, Hazard ES, Hardiman G, et al. Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma. Oncogene. 2017;36:3137–48.
pubmed: 27941877
doi: 10.1038/onc.2016.451
de Sousa GF, de Lima MA, Custodio DF, Freitas VM, Monteiro G. Chemogenomic study of carboplatin in saccharomyces cerevisiae: inhibition of the NEDDylation process overcomes cellular resistance mediated by hur and cullin proteins. PLoS ONE. 2015;10:e0145377.
pubmed: 26692264
pmcid: 4686384
doi: 10.1371/journal.pone.0145377
Korshunov A, Golanov A, Sycheva R, Pronin I. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol. 1999;52:574–80.
pubmed: 10645226
pmcid: 500947
doi: 10.1136/jcp.52.8.574
Papatheofani V, Levidou G, Sarantis P, Koustas E, Karamouzis MV, Pergaris A, et al. HuR protein in hepatocellular carcinoma: implications in development. Progn Treat Biomed. 2021;9:119.
Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci. 1995;20:465–70.
pubmed: 8578590
doi: 10.1016/S0968-0004(00)89102-1
Chen C-YA, Xu N, Shyu A-B. Highly selective actions of HuR in antagonizing AU-rich element-mediated mRNA destabilization. Mol Cell Biol. 2002;22:7268–78.
pubmed: 12242302
pmcid: 139819
doi: 10.1128/MCB.22.20.7268-7278.2002
Gallouzi IE, Brennan CM, Steitz JA. Protein ligands mediate the CRM1-dependent export of HuR in response to heat shock. RNA. 2001;7:1348–61.
pubmed: 11565755
pmcid: 1370177
doi: 10.1017/S1355838201016089
Yiakouvaki A, Dimitriou M, Karakasiliotis I, Eftychi C, Theocharis S, Kontoyiannis DL. Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis. J Clin Invest. 2012;122:48–61.
pubmed: 22201685
doi: 10.1172/JCI45021
Rhee WJ, Ni C-W, Zheng Z, Chang K, Jo H, Bao G. HuR regulates the expression of stress-sensitive genes and mediates inflammatory response in human umbilical vein endothelial cells. Proc Natl Acad Sci USA. 2010;107:6858–63.
pubmed: 20351266
pmcid: 2872448
doi: 10.1073/pnas.1000444107
Zhang J, Modi Y, Yarovinsky T, Yu J, Collinge M, Kyriakides T, et al. Macrophage β2 integrin-mediated, HuR-dependent stabilization of angiogenic factor-encoding mRNAs in inflammatory angiogenesis. Am J Pathol. 2012;180:1751–60.
pubmed: 22322302
pmcid: 3349897
doi: 10.1016/j.ajpath.2011.12.025
Kotta-Loizou I, Giaginis C, Theocharis S. Clinical significance of HuR expression in human malignancy. Med Oncol. 2014;31:161.
pubmed: 25112469
doi: 10.1007/s12032-014-0161-y
de López SI, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol. 2005;2:11–3.
doi: 10.4161/rna.2.1.1552
Ghosh M, Aguila HL, Michaud J, Ai Y, Wu M-T, Hemmes A, et al. Essential role of the RNA-binding protein HuR in progenitor cell survival in mice. J Clin Invest. 2009;119:3530–43.
pubmed: 19884656
pmcid: 2786787
doi: 10.1172/JCI38263
von Roretz C, Beauchamp P, Di Marco S, Gallouzi I-E. HuR and myogenesis: being in the right place at the right time. Biochim Biophys Acta. 2011;1813:1663–7.
doi: 10.1016/j.bbamcr.2011.01.036
Ouhara K, Munenaga S, Kajiya M, Takeda K, Matsuda S, Sato Y, et al. The induced RNA‐binding protein, HuR, targets 3′‐UTR region of IL‐6 mRNA and enhances its stabilization in periodontitis. Clin Exp Immunol [Internet]. 2018 [cited 2022 Feb 25]; 192:325–36. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980314/
Chen J, Cascio J, Magee JD, Techasintana P, Gubin MM, Dahm GM, et al. Posttranscriptional gene regulation of IL-17 by the RNA-binding protein HuR is required for initiation of experimental autoimmune encephalomyelitis. J Immunol [Internet]. 2013 [cited 2022 Feb 25]; 191:5441–50. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831112/
Liu Y, Wei W, Wang Y, Wan C, Bai Y, Sun X, et al. TNF-α/calreticulin dual signaling induced NLRP3 inflammasome activation associated with HuR nucleocytoplasmic shuttling in rheumatoid arthritis. Inflamm Res. 2019;68:597–611.
pubmed: 31119302
doi: 10.1007/s00011-019-01244-w
Zou H, Shao C-X, Zhou Q-Y, Zhu G-Q, Shi K-Q, Braddock M, et al. The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention. Expert Rev Gastroenterol Hepatol. 2016;10:331–40.
pubmed: 26558504
doi: 10.1586/17474124.2016.1116382
Lin F-Y, Chen Y-H, Lin Y-W, Tsai J-S, Chen J-W, Wang H-J, et al. The role of human antigen R, an RNA-binding protein, in mediating the stabilization of toll-like receptor 4 mRNA induced by endotoxin: a novel mechanism involved in vascular inflammation. Arterioscler Thromb Vasc Biol. 2006;26:2622–9.
pubmed: 16990552
doi: 10.1161/01.ATV.0000246779.78003.cf
Shang J, Zhao Z. Emerging role of HuR in inflammatory response in kidney diseases. Acta Biochim Biophys Sin (Shanghai). 2017;49:753–63.
pubmed: 28910975
doi: 10.1093/abbs/gmx071
Liu R, Wu K, Li Y, Sun R, Li X. Human antigen R: a potential therapeutic target for liver diseases. Pharmacol Res. 2020;155: 104684.
pubmed: 32045667
doi: 10.1016/j.phrs.2020.104684
Green LC, Anthony SR, Slone S, Lanzillotta L, Nieman ML, Wu X, et al. Human antigen R as a therapeutic target in pathological cardiac hypertrophy. JCI Insight. 2019;4: 121541.
pubmed: 30668549
doi: 10.1172/jci.insight.121541
Abdelmohsen K, Lal A, Kim HH, Gorospe M. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle. 2007;6:1288–92.
pubmed: 17534146
doi: 10.4161/cc.6.11.4299
Levidou G, Kotta-Loizou I, Tasoulas J, Papadopoulos T, Theocharis S. Clinical significance and biological role of HuR in head and neck carcinomas. Dis Markers. 2018;2018:4020937.
pubmed: 29619127
pmcid: 5829322
doi: 10.1155/2018/4020937
Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci. 2001;58:266–77.
pubmed: 11289308
doi: 10.1007/PL00000854
Vázquez-Chantada M, Fernández-Ramos D, Embade N, Martínez-Lopez N, Varela-Rey M, Woodhoo A, et al. HuR/methyl-HuR and AUF1 regulate the MAT expressed during liver proliferation, differentiation, and carcinogenesis. Gastroenterology. 2010;138:1943–53.
pubmed: 20102719
doi: 10.1053/j.gastro.2010.01.032
Embade N, Fernández-Ramos D, Varela-Rey M, Beraza N, Sini M, de Gutiérrez JV, et al. Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology. 2012;55:1237–48.
pubmed: 22095636
doi: 10.1002/hep.24795
Zhu H, Berkova Z, Mathur R, Sehgal L, Khashab T, Tao R-H, et al. HuR suppresses fas expression and correlates with patient outcome in liver cancer. Mol Cancer Res. 2015;13:809–18. https://doi.org/10.1158/1541-7786.MCR-14-0241 . (cited 2022 Feb 28).
doi: 10.1158/1541-7786.MCR-14-0241
pubmed: 25678597
Woodhoo A, Iruarrizaga-Lejarreta M, Beraza N, García-Rodríguez JL, Embade N, Fernández-Ramos D, et al. Human antigen R contributes to hepatic stellate cell activation and liver fibrosis. Hepatology. 2012;56:1870–82.
pubmed: 22576182
doi: 10.1002/hep.25828
Zou Z, Ma T, He X, Zhou J, Ma H, Xie M, et al. Long intergenic non-coding RNA 00324 promotes gastric cancer cell proliferation via binding with HuR and stabilizing FAM83B expression. Cell Death Dis. 2018;9:717.
pubmed: 29915327
pmcid: 6006375
doi: 10.1038/s41419-018-0758-8
Hu Y-P, Jin Y-P, Wu X-S, Yang Y, Li Y-S, Li H-F, et al. Correction to: LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis. Mol Cancer. 2021;20:110.
pubmed: 34454521
pmcid: 8400894
doi: 10.1186/s12943-021-01386-8
Watanabe R, Ui A, Kanno S, Ogiwara H, Nagase T, Kohno T, et al. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and Show interdependent protein stability. Cancer Res. 2014;74:2465–75. https://doi.org/10.1158/0008-5472.CAN-13-3608 . (cited 2022 Feb 27).
doi: 10.1158/0008-5472.CAN-13-3608
pubmed: 24788099
Andrade D, Mehta M, Griffith J, Oh S, Corbin J, Babu A, et al. HuR reduces radiation-induced DNA damage by enhancing expression of ARID1A. Cancers (Basel) [Internet]. 2019 [cited 2022 Feb 27]; 11:2014. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966656/
Srikantan S, Abdelmohsen K, Lee EK, Tominaga K, Subaran SS, Kuwano Y, et al. Translational control of TOP2A influences doxorubicin efficacy. Mol Cell Biol. 2011;31:3790–801.
pubmed: 21768308
pmcid: 3165726
doi: 10.1128/MCB.05639-11
Filippova N, Nabors LB. ELAVL1 role in cell fusion and tunneling membrane nanotube formations with implication to treat glioma heterogeneity. Cancers (Basel) [Internet]. 2020 [cited 2022 Mar 1]; 12:3069. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590168/
Yang W, Yu H, Shen Y, Liu Y, Yang Z, Sun T. MiR-146b-5p overexpression attenuates stemness and radioresistance of glioma stem cells by targeting HuR/lincRNA-p21/β-catenin pathway. Oncotarget. 2016;7:41505–26.
pubmed: 27166258
pmcid: 5173075
doi: 10.18632/oncotarget.9214
Mehta M, Basalingappa K, Griffith JN, Andrade D, Babu A, Amreddy N, et al. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget [Internet]. 2016 [cited 2022 Feb 27]; 7:64820–35. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323119/
Dhir T, Schultz CW, Jain A, Brown SZ, Haber A, Goetz A, et al. Abemaciclib is effective against pancreatic cancer cells and synergizes with HuR and YAP1 inhibition. Mol Cancer Res [Internet]. 2019 [cited 2022 Feb 28]; 17:2029–41. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794000/
Zhu Z, Zhao Y, Li J, Tao L, Shi P, Wei Z, et al. Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol Carcinog. 2016;55:1399–410.
pubmed: 26310813
doi: 10.1002/mc.22383
Latorre E, Castiglioni I, Gatto P, Carelli S, Quattrone A, Provenzani A. Loss of protein kinase Cδ/HuR Interaction is necessary to doxorubicin resistance in breast cancer cell lines. J Pharmacol Exp Ther [Internet]. Am Soc Pharmacol Exp Therapeutics; 2014 [cited 2022 Feb 21]; 349:99–106. Available from: https://jpet.aspetjournals.org/content/349/1/99
Thorne JL, Battaglia S, Baxter DE, Hayes JL, Hutchinson SA, Jana S, et al. MiR-19b non-canonical binding is directed by HuR and confers chemosensitivity through regulation of P-glycoprotein in breast cancer. Biochimica et Biophysica Acta (BBA)—Gene Regulatory Mech [Internet]. 2018 [cited 2022 Feb 27]; 1861:996–1006. Available from: https://www.sciencedirect.com/science/article/pii/S187493991830213X
Tan S, Ding K, Chong Q-Y, Zhao J, Liu Y, Shao Y, et al. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. J Biological Chem [Internet]. American Society for Biochemistry and Molecular Biology; 2017 [cited 2022 Feb 27]; 292:13551. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566515/
Han J, Qu H, Han M, Ding Y, Xie M, Hu J, et al. MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer. Oncogene [Internet]. Nat Publishing Group; 2021 [cited 2022 Feb 22]; 40:833–47. Available from: https://www.nature.com/articles/s41388-020-01574-8
Li Y, Yu J, Du D, Fu S, Chen Y, Yu F, et al. Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells. Oncol Lett. 2013;6:156–60.
pubmed: 23946796
pmcid: 3742653
doi: 10.3892/ol.2013.1352
Tan D, Li G, Zhang P, Peng C, He B. LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells. Bioengineered [Internet]. [cited 2022 Feb 11]; 13:1838–57. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805932/
Zhou Y, Chang R, Ji W, Wang N, Qi M, Xu Y, et al. Loss of scribble promotes snail translation through translocation of HuR and enhances cancer drug resistance. J Biol Chem [Internet]. 2016 [cited 2022 Feb 21]; 291:291–302. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697165/
Yao Y, Chu H, Wang J, Wang B. Decreased human antigen R expression confers resistance to tyrosine kinase inhibitors in epidermal growth factor receptor-mutant lung cancer by inhibiting Bim expression. Int J Mol Med. 2018;42:2930–42.
pubmed: 30226552
Zhang K, Chen J, Li C, Yuan Y, Fang S, Liu W, et al. Exosome-mediated transfer of SNHG7 enhances docetaxel resistance in lung adenocarcinoma. Cancer Lett. 2022;526:142–54.
pubmed: 34715254
doi: 10.1016/j.canlet.2021.10.029
Liu Y, Chang M, Hu Z, Xu X, Wu W, Ning M, et al. Danggui Buxue Decoction enhances the anticancer activity of gemcitabine and alleviates gemcitabine-induced myelosuppression. J Ethnopharmacol. 2021;273: 113965.
pubmed: 33639205
doi: 10.1016/j.jep.2021.113965
Deng X, Ruan H, Zhang X, Xu X, Zhu Y, Peng H, et al. Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. Int J Cancer. 2020;146:1700–16. https://doi.org/10.1002/ijc.32608 . (cited 2022 Feb 28).
doi: 10.1002/ijc.32608
pubmed: 31381140
Cai J, Wang H, Jiao X, Huang R, Qin Q, Zhang J, et al. The RNA-binding protein HuR confers oxaliplatin resistance of colorectal cancer by upregulating CDC6. Mol Cancer Therapeutics. 2019;18:1243–54. https://doi.org/10.1158/1535-7163.MCT-18-0945 .
doi: 10.1158/1535-7163.MCT-18-0945
To KKW, Leung WW, Ng SSM. Exploiting a novel miR-519c–HuR–ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res [Internet]. 2015 [cited 2022 Feb 28]; 338:222–31. Available from: https://www.sciencedirect.com/science/article/pii/S001448271530094X
Lin G-L, Ting H-J, Tseng T-C, Juang V, Lo Y-L. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells. PLoS One [Internet]. 2017 [cited 2022 Feb 28]; 12:e0185625. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624618/
Badawi A, Biyanee A, Nasrullah U, Winslow S, Schmid T, Pfeilschifter J, et al. Inhibition of IRES-dependent translation of caspase-2 by HuR confers chemotherapeutic drug resistance in colon carcinoma cells. Oncotarget. 2018;9:18367–85.
pubmed: 29719611
pmcid: 5915078
doi: 10.18632/oncotarget.24840
Liu H, Song X, Hou J, Zhao Z, Chang J. Posttranscriptional regulation of human antigen R by miR-133b Enhances docetaxel cytotoxicity through the inhibition of ATP-binding cassette subfamily G member 2 in prostate cancer cells. DNA Cell Biol [Internet]. Mary Ann Liebert, Inc., publishers; 2018 [cited 2022 Feb 28]; 37:210–9. Available from: https://www.liebertpub.com/doi/full/ https://doi.org/10.1089/dna.2017.3940
Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate [Internet]. 2010 [cited 2022 Feb 28]; 70:1501–12. Available from: https://onlinelibrary.wiley.com/doi/abs/ https://doi.org/10.1002/pros.21185
Li W, Luo L, Shi W, Yin Y, Gao S. Ursolic acid reduces Adriamycin resistance of human ovarian cancer cells through promoting the HuR translocation from cytoplasm to nucleus. Environ Toxicol. 2021;36:267–75.
pubmed: 33009882
doi: 10.1002/tox.23032
Huang Y-H, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, et al. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget [Internet]. 2016 [cited 2022 Feb 27]; 7:21812–24. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008325/
Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, et al. MiR-200c and HuR in ovarian cancer. BMC Cancer [Internet]. 2013 [cited 2022 Feb 27]; 13:72. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576328/
Toyota K, Murakami Y, Kondo N, Uemura K, Nakagawa N, Takahashi S, et al. Cytoplasmic Hu-antigen R (HuR) expression is associated with poor survival in patients with surgically resected cholangiocarcinoma treated with adjuvant gemcitabine-based chemotherapy. Ann Surg Oncol. 2018;25:1202–10.
pubmed: 29492748
doi: 10.1245/s10434-018-6392-y
Liu Z-M, Tseng JT, Hong D-Y, Huang H-S. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells. Biochem J. 2011;438:349–58. https://doi.org/10.1042/BJ20101653 . (cited 2022 Feb 28).
doi: 10.1042/BJ20101653
pubmed: 21649584
Fernandez M, Sutterlüty‐Fall H, Schwärzler C, Lemeille S, Boehncke W, Merat R. Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition. Cancer Med [Internet]. 2017 [cited 2022 Feb 28]; 6:1652–64. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504324/
McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, et al. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer. Cancer Biol Ther [Internet]. 2014 [cited 2022 Feb 28]; 15:688–98. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049785/
Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, et al. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One [Internet]. 2010 [cited 2022 Feb 28]; 5:e15455. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994932/
Costantino CL, Witkiewicz AK, Y YK, Cozzitorto JA, Kennedy EP, Dasgupta A, et al. HuR’s role in gemcitabine efficacy in pancreatic cancer: HuR upregulates the expression of the gemcitabine metabolizing enzyme, deoxycytidine kinase. Cancer Res [Internet]. 2009 [cited 2022 Feb 28]; 69:4567–72. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744447/
Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, et al. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg. 2010;252:499–505 (discussion 505–506).
pubmed: 20739850
doi: 10.1097/SLA.0b013e3181f1fd44
Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A, Dambrauskas Z. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J Gastroenterol [Internet]. 2015 [cited 2022 Mar 1]; 21:13004–19. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674719/
Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, et al. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Res. 2017;77:4460–71.
pubmed: 28652247
pmcid: 5922269
doi: 10.1158/0008-5472.CAN-17-0015
Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, et al. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res. 2014;74:1128–40.
pubmed: 24536047
pmcid: 4353573
doi: 10.1158/0008-5472.CAN-13-1915
Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, et al. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP in hibitors. Cancer Res. 2017;77:5011–25.
pubmed: 28687616
pmcid: 5663502
doi: 10.1158/0008-5472.CAN-16-2704
Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, et al. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells. Mol Cancer Res [Internet]. 2016 [cited 2022 Feb 28]; 14:599–611. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312260/
Blanco F, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, et al. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene [Internet]. 2016 [cited 2022 Feb 28]; 35:2529–41. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818728/
Filippova N, Yang X, Wang Y, Gillespie GY, Langford C, King PH, et al. The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res. 2011;9:648–59.
pubmed: 21498545
pmcid: 3096748
doi: 10.1158/1541-7786.MCR-10-0325
Xiao K, Yang L, Gao X, An Y, Xie W, Jingquan G. HuR Affects proliferation and apoptosis of chronic lymphocytic leukemia cells via NF-κB pathway. Biomed Res Int [Internet]. 2020 [cited 2022 Feb 22]; 2020:1481572. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474742/
Chiou J-T, Lee Y-C, Huang C-H, Shi Y-J, Wang L-J, Chang L-S. Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells. Toxicology and Applied Pharmacology [Internet]. 2020 [cited 2022 Feb 22]; 387:114857. Available from: https://www.sciencedirect.com/science/article/pii/S0041008X1930465X
Zhang F, Ni H, Li X, Liu H, Xi T, Zheng L. LncRNA FENDRR attenuates adriamycin resistance via suppressing MDR1 expression through sponging HuR and miR-184 in chronic myelogenous leukaemia cells. FEBS Lett. 2019;593:1993–2007.
pubmed: 31180580
doi: 10.1002/1873-3468.13480
Xu W, Chen C, Xu R, Li Y, Hu R, Li Z, et al. Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents. Biomed Pharmacother. 2018;102:587–93.
pubmed: 29597092
doi: 10.1016/j.biopha.2018.03.098
Ahmed R, Amreddy N, Babu A, Munshi A, Ramesh R. Combinatorial nanoparticle delivery of siRNA and antineoplastics for lung cancer treatment. Methods Mol Biol. 2019;1974:265–90.
pubmed: 31099010
doi: 10.1007/978-1-4939-9220-1_20
Muralidharan R, Babu A, Amreddy N, Basalingappa K, Mehta M, Chen A, et al. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnol [Internet]. 2016 [cited 2022 Feb 20]; 14:47. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915183/
Ahmed R, Muralidharan R, Srivastava A, Johnston SE, Zhao YD, Ekmekcioglu S, et al. Molecular targeting of HuR oncoprotein suppresses MITF and induces apoptosis in melanoma cells. Cancers (Basel). 2021;13:E166.
doi: 10.3390/cancers13020166
Wang Z, Bhattacharya A, Ivanov DN. Identification of small-molecule inhibitors of the HuR/RNA interaction using a fluorescence polarization screening assay followed by NMR validation. PLoS ONE. 2015;10: e0138780.
pubmed: 26390015
pmcid: 4577092
doi: 10.1371/journal.pone.0138780
Blanco FF, Preet R, Aguado A, Vishwakarma V, Stevens LE, Vyas A, et al. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget. 2016;7:74043–58.
pubmed: 27677075
pmcid: 5342034
doi: 10.18632/oncotarget.12189
Wang J, Hjelmeland AB, Nabors LB, King PH. Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells. Cancer Biol Ther. 2019;20:979–88.
pubmed: 30991885
pmcid: 6606032
doi: 10.1080/15384047.2019.1591673
Filippova N, Yang X, Ananthan S, Calano J, Pathak V, Bratton L, et al. Targeting the HuR oncogenic role with a new class of cytoplasmic dimerization inhibitors. Cancer Res. 2021;81:2220–33.
pubmed: 33602784
pmcid: 8137579
doi: 10.1158/0008-5472.CAN-20-2858
Lee J-Y, Chung T-W, Choi H-J, Lee CH, Eun JS, Han YT, et al. A novel cantharidin analog N-benzylcantharidinamide reduces the expression of MMP-9 and invasive potentials of Hep3B via inhibiting cytosolic translocation of HuR. Biochem Biophys Res Commun. 2014;447:371–7.
pubmed: 24735540
doi: 10.1016/j.bbrc.2014.04.035
Doller A, Badawi A, Schmid T, Brauss T, Pleli T, zu Heringdorf DM, et al. The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. Exp Cell Res. 2015; 330:66–80.
Eberhardt W, Badawi A, Biyanee A, Pfeilschifter J. Cytoskeleton-dependent transport as a potential target for interfering with post-transcriptional HuR mRNA regulons. Front Pharmacol. 2016;7:251.
pubmed: 27582706
pmcid: 4987335
doi: 10.3389/fphar.2016.00251
Lebedeva S, Jens M, Theil K, Schwanhäusser B, Selbach M, Landthaler M, et al. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. Mol Cell. 2011;43:340–52.
pubmed: 21723171
doi: 10.1016/j.molcel.2011.06.008
Allegri L, Baldan F, Roy S, Aubé J, Russo D, Filetti S, et al. The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells. Sci Rep. 2019;9:7374.
pubmed: 31089242
pmcid: 6517587
doi: 10.1038/s41598-019-43894-0
Muralidharan R, Mehta M, Ahmed R, Roy S, Xu L, Aubé J, et al. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci Rep [Internet]. 2017 [cited 2022 Feb 20]; 7:9694. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577245/
Wu X, Gardashova G, Lan L, Han S, Zhong C, Marquez RT, et al. Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis. Commun Biol. 2020;3:193.
pubmed: 32332873
pmcid: 7181695
doi: 10.1038/s42003-020-0933-1
Chae M-J, Sung HY, Kim E-H, Lee M, Kwak H, Chae CH, et al. Chemical inhibitors destabilize HuR binding to the AU-rich element of TNF-alpha mRNA. Exp Mol Med. 2009;41:824–31.
pubmed: 19949288
pmcid: 2788736
doi: 10.3858/emm.2009.41.11.088